Penel et al developed a bedside score to predict early death of a patient with metastatic cancer from an unknown primary. The authors are from hospitals in France and Canada.
Patient selection: metastatic cancer from an unknown primary
Outcome: 90 day (3 month) mortality
Parameters:
(1) ECOG performance scale
(2) number of comorbidities requiring treatment
(3) serum LDH
(4) serum albumin or total protein
Parameter |
Finding |
Points |
---|---|---|
ECOG performance |
0 or 1 |
0 |
|
2, 3 or 4 |
1 |
number of comorbidities |
0 |
0 |
|
1 or more |
1 |
serum LDH |
up to 1.5 times the upper limite of the normal reference range |
0 |
|
more than 1.5 times the upper limit of normal |
1 |
serum albumin or protein |
albumin >= 35 g/L AND total protein >= 70 g/L |
0 |
|
albumin < 35 g/L OR total protein < 70 g/L |
1 |
number of risk factors =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 4
• The higher the score the greater the mortality rate at 90 days.
Score |
90 Day Mortality |
---|---|
0 or 1 |
13% |
2 |
25-32% |
3 or 4 |
64% |
Purpose: To predict the 90 day mortality rate for a patient with metastases from a cancer with an unknown primary site as reported by Penel et al.
Specialty: Hematology Oncology, Surgery, general
Objective: risk factors, severity, prognosis, stage
ICD-10: Z51.5, C79.9, C00-C97,